Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2000

View Archived Issues

Favorable safety and efficacy data reported for Concerta; FDA issues approvable letter

Clinical trial of Emitasol completed

Shire buys rights to sell ulcerative colitis treatment in Europe

Antisoma temporarily halts Theragyn phase III enrollment

Clonidine may help reduce tamoxifen-induced hot flashes in breast cancer patients

Ropinirole reduces the risk of dyskinesia in early Parkinson's disease

Vertex receives USD 10 million from Aventis for new drugs targeting inflammatory diseases

Two neuroscience companies to merge

Celecoxib studies reported at DDW

News from DDW: update on Gastrimmune clinical studies

CVT-124 assessed in cirrhotic patients with ascites

FMdC and gemcitabine compared in pancreatic cancer xenograft model

Gastroduodenal effects of parecoxib assessed in the elderly

New class of microtubule assembly inhibitors discovered by the former RPR

French research team designs highly potent and selective human B1 receptor antagonists

Phase I trial of Hu1D10 continues following positive results in first lymphoma patients treated

New fusion toxin with therapeutic potential in acute-phase CML presented at ASCO

Roche withdraws application to CPMP for Tamiflu; resubmission planned in near future

Single doses of HspE7 are well tolerated and elicit specific cell-mediated immunity

Aronex reports clinical results for Atragen in APL and renal cell cancer at ASCO meeting

Potential new antidepressants under study at Welfide

Microbial metabolite discovered by Banyu to have antitumor activity

Cell adhesion inhibitors under development at Kyorin

L-Glu-L-Trp analogues with advantages over parent compound

Pfizer's new adenosine A2A receptor agonists useful for respiratory and inflammatory diseases

Epibatidine analogues with high affinity for nicotinic acetylcholine receptors

Anxiolytic agents from MS&D targeting a GABA-A receptor subunit

New inhibitors of cytokine production with a 5-aminoisoxazole moiety

CPMP recommends approval of Herceptin for treatment of metastatic breast cancer

Advantages of Specific RAAS Blockage -- Internet Webcast available to Daily Essentials readers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...